Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Tim-3/CD123 CAR-T for r/r AML
NCT06125652Phase 2Recruiting
- Sponsor
- Xuzhou Medical University
- Start
- Nov 2023
- Primary completion
- Jan 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti Tim-3/CD123 CAR-T cell therapy in acute myeloid leukemia (AML), sponsored by Xuzhou Medical University. Started Nov 2023; status: recruiting.
02
Drugs
anti Tim-3/CD123 CAR-T cell therapy
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06125652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125652.